AbbVie Inc.

Muted response to launch of $1.75bn partnership with Regenxbio

55
Following 7% drop after FDA calls for arthritis drug to be labelled with heart-risk warning

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.